12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RhLAL: Interim Phase I/II data

Interim data from an open-label, international Phase I/II trial in 9 patients with liver dysfunction due to late onset LAL deficiency showed that 4 weekly infusions of 0.35, 1 or 3 mg/kg SBC-102 were...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >